摘要
The cholinergic anti-inflammatory pathway(CAP)refers to the anti-inflammatory effects mediated by the parasympathetic nervous system.Existence of this pathway was first demonstrated when acetylcholinesterase inhibitors showed benefits in animal models of sepsis.CAP functions via the vagus nerve.The systemic antiinflammatory effects of CAP converges on theα7 nicotinic acetylcholine receptor on splenic macrophages,leading to suppression of pro-inflammatory cytokines and simultaneous stimulation of anti-inflammatory cytokines,including interleukin 10.CAP offers a novel mechanism to mitigate inflammation.Electrical vagal nerve stimulation has shown benefits in patients suffering from rheumatoid arthritis.Direct agonists like nicotine and GTS-1 have also demonstrated antiinflammatory properties in models of sepsis and acute respiratory distress syndrome,as have acetylcholinesterase inhibitors like Galantamine and Physostigmine.Experience with coronavirus disease 2019(COVID-19)induced acute respiratory distress syndrome indicates that immunomodulators have a protective role in patient outcomes.Dexamethasone is the only medication currently in use that has shown to improve clinical outcomes.This is likely due to the suppression of what is referred to as a cytokine storm,which is implicated in the lethality of viral pneumonia.Nicotine transdermal patch activates CAP and harvests its anti-inflammatory potential by means of an easily administered depot delivery mechanism.It could prove to be a promising,safe and inexpensive additional tool in the currently limited armamentarium at our disposal for management of COVID-19 induced acute hypoxic respiratory failure.
